Cargando…

Decoding the Pathophysiology of HFpEF With High-Resolution Phenotyping

[Figure: see text]

Detalles Bibliográficos
Autor principal:	Houstis, Nicholas E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091496/ https://www.ncbi.nlm.nih.gov/pubmed/32215376 http://dx.doi.org/10.1016/j.jacbts.2020.02.003

Ejemplares similares

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

Understanding HFpEF With Obesity: Will Pigs Come to the Rescue?
por: Kass, David A.
Publicado: (2021)

Turning Pressure Into Success: Preload Restriction in HFpEF?
por: Atkins, Jessica, et al.
Publicado: (2021)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

The Bslc2(–/–) Mouse: Adding a Missing Phenotype to the Repertoire of HFpEF Animal Models
por: Salloum, Fadi N., et al.
Publicado: (2019)

More Energy to Relax: Targeting Epigenetic Effects of Acute Renal Injury to Prevent HFpEF
por: Diwan, Abhinav
Publicado: (2021)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
por: Ha, Chae-Myeong, et al.
Publicado: (2019)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

A potential role of autophagy-mediated vascular senescence in the pathophysiology of HFpEF
por: Sanhueza-Olivares, Fernanda, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF
por: Zhang, Yuhua, et al.
Publicado: (2022)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants
por: Hiebert, John B., et al.
Publicado: (2016)

Diet-Induced Obesity HFpEF Murine Models
por: Carbone, Salvatore, et al.
Publicado: (2018)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
por: Bonanni, Alice, et al.
Publicado: (2023)

The role of imaging in the selection of patients for HFpEF therapy
por: Baron, Tomasz, et al.
Publicado: (2023)

Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance
por: Berlot, Bostjan, et al.
Publicado: (2019)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
por: Li, Zheng, et al.
Publicado: (2023)

OR19-2 Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) with Low and High Dose of Triiodothyronine: an Animal Model of Metabolic Syndrome with HFpEF
por: Almeida-Coelho, João, et al.
Publicado: (2022)

Trimming the Fat in HFpEF: Learning How to Target the Metabolic Disease Phenotype
por: Schilling, Joel D.
Publicado: (2020)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
por: Morfino, Paolo, et al.
Publicado: (2022)

The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes
por: Lyle, Melissa A., et al.
Publicado: (2019)

Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design
por: Ali, Danish, et al.
Publicado: (2019)

Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
por: Cuijpers, Ilona, et al.
Publicado: (2020)

Reply: Diet-Induced Obesity HFpEF Murine Models
por: Valero-Muñoz, Maria, et al.
Publicado: (2018)

Cat-apulting Toward a Molecular Understanding of HFpEF
por: Robinson, Emma L., et al.
Publicado: (2021)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
por: Arvidsson, Per M., et al.
Publicado: (2022)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
por: Zhu, Zhaowei, et al.
Publicado: (2021)

Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?
por: Justo da Silva, Gustavo Jose, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oqvhes5k96jldrjccb2ghno8aq